Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Litigation Details for Shire ViroPharma LLC v. CSL Behring LLC (D. Del. 2017)

Email this page to a colleague

« Back to Dashboard

Shire ViroPharma LLC v. CSL Behring LLC (D. Del. 2017)

Docket	⤷ Try it Free	Date Filed	2017-04-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	Plaintiff	Referred To
Patents	10,080,788; 10,201,595
Link to Docket	External link to docket

Biologic Drugs cited in Shire ViroPharma LLC v. CSL Behring LLC

The biologic drug covered by the patents cited in this case is ⤷ Try it Free .

Details for Shire ViroPharma LLC v. CSL Behring LLC (D. Del. 2017)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Date Filed	Document No.	Description	Snippet	Link To Document
2019-02-11	140		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,616,111 ;10,080,788 ;10,105,423 ;…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware	External link to document
2019-04-23	162	Notice of Service	Intrinsic Evidence for Identified Terms of U.S. Patent Nos. 10,080,788, 10,105,423, 10,130,690 and 10,201,595 …11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware	External link to document
2019-06-13	190	Answer to Complaint	First Amended Counterclaims Concerning U.S. Patent Nos. 10,080,788; 10,105,432; 10,130,690; and 10,201,595…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware	External link to document
2019-06-20	201	Redacted Document	First Amended Counterclaims Concerning U.S. Patent Nos. 10,080,788; 10,105,432; 10,130,690; and 10,201,595…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware	External link to document
2019-08-05	216	Opinion - Memorandum Opinion	that a fourth continuation patent—Patent No. 10,201,595 (the “’595 Patent”)—would issue on February …more claims of Shire’s ’788 Patent, ’423 Patent, ’690 Patent, and ’595 Patent. (Id. ¶¶ 32– 100.) …at least claim 1 of the ’788 Patent, the ’423 Patent, and the ’690 Patent. The PTO then indicated that…¶¶ 14–19.) B. The Patents-in-Suit 1. The ’788 Patent On September 25, 2018…2018, the United States Patent and Trademark Office (“PTO”) issued the ’788 Patent, entitled “C1-INH Compositions	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Boehringer Ingelheim

McKesson

Medtronic

Moodys

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.